Profitelligence Profitelligence · Filing Ledger Open DXCM research →

Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-07-31

Foletta Mark G Files Dexcom (DXCM) Form 4 - July 31, 2026

Foletta Mark G sold 4.0K DXCM shares worth $330.6K in this Form 4 filing, reported to the SEC on 2026-07-31.

Insider
Foletta Mark G
Issuer
Dexcom Inc. DXCM · NASDAQ
Filed
Period
2026-07-31
Accession
0001093557-26-000145

Transactions (2)

Insider Date Type Shares Price Value Own
Foletta Mark G 2026-08-03 Sell 2.0K $85.32 $170.6K Indirect
Foletta Mark G 2026-07-31 Sell 2.0K $80.00 $160.0K Indirect
Net change−4.0K−$330.6K

About Dexcom Inc.

Dexcom Inc. is a prominent player in the medical technology sector, specializing in continuous glucose monitoring (CGM) systems for diabetes management. The company's primary function is to develop and distribute innovative CGM devices that provide real-time glucose readings, allowing individuals with diabetes to make informed decisions about their health. Dexcom’s products play a critical role in healthcare by offering an alternative to traditional fingerstick testing, thus improving quality of life for many users. The company impacts several sectors, most notably within healthcare and technology, by integrating advanced data analytics and wireless technology into its monitoring systems. This not only aids individuals in managing their glucose levels but also supports healthcare providers in delivering better patient care through data-driven insights. In the financial market, Dexcom Inc. is recognized for its contributions to the growing field of digital health solutions. The company has established itself as a leader in its niche, continuously pushing the boundaries of technology to offer more precise and user-friendly glucose monitoring options. Founded in 1999 and headquartered in San Diego, California, Dexcom remains at the forefront of diabetes management solutions.

Exchange NASDAQ Industry Medical Devices Company website ↗

Track DXCM insider activity

Get alerted when Dexcom Inc. executives buy or sell their shares.

Set up free alerts